AMGN
US EQUITY
Health Care
Biotechnology
CIK: 318154
Amgen (AMGN) Quant Factor Diagnostic & Fair Value Model
Amgen (Ticker: AMGN) is listed in the Health Care sector (Biotechnology). Below is its point-in-time financial profile, valuation multiples, and cross-sectional factor diagnostics.
$439.26
-1.79%
Latest Close (2026-10-23)
Market Cap: -
P/E Ratio: 25.1
Momentum Strength
3M / 12M
+16.74%
1M: +8.18%
12M: +48.41%
Quality (ROE)
Point-in-Time
+13.54%
Trailing Return on Equity
Technical Trend
RSI 14
69.5
SMA50: $417.26
SMA200: $371.61
Valuation Multiplier
Trailing
25.1
Moderate Valuation Corridor (15x - 30x P/E)
📊
Valuation & Multi-Factor Diagnostic
Moderate Valuation Corridor (15x - 30x P/E)
AMGN trades within a typical sector multiple band (25.1x P/E), broadly aligned with trailing earnings.
⚡
Benchmark Factor Strategy
S&P 500 Momentum Alpha Strategy
This strategy applies cross-sectional momentum and quality factor filters across large-cap US equities.
📈 Daily Candlestick & Volume Quant Chart
Interactive lightweight price action & volume breakdown over recent 90 trading days.
均线多头 (MA20/50)
Piotroski F-Score: 8/9 (High Financial Strength)
Official Point-in-Time Financial Filing History
Zero Lookahead Bias: Every financial metric is timestamped at the exact moment officially published to the market.
备案 CIK: 318154 · 10-K 年报 / 10-Q 季报
| Form | Period End | Filing Timestamp (Point-in-Time) | Revenue | Net Income | Operating CF | EPS (Diluted) |
|---|---|---|---|---|---|---|
| 10-Q | 2026-06-30 | 2026-08-05 | - | $2.38B | $6.19B | $4.37 |
| 10-Q | 2025-12-31 | 2026-08-05 | - | - | - | - |
| 10-Q | 2025-06-30 | 2026-08-05 | - | $1.43B | $3.67B | $2.65 |
| 10-Q | 2026-03-31 | 2026-05-01 | - | $1.82B | $2.19B | $3.34 |
| 10-Q | 2025-03-31 | 2026-05-01 | - | $1.73B | $1.39B | $3.20 |
| 10-K | 2025-12-31 | 2026-02-13 | - | $7.71B | $9.96B | $14.23 |
| 10-K | 2024-12-31 | 2026-02-13 | - | $4.09B | $11.49B | $7.56 |
| 10-K | 2023-12-31 | 2026-02-13 | - | $6.72B | $8.47B | $12.49 |
💡 Methodology & Frequently Asked Questions
Key reference details regarding Amgen (AMGN) valuation multiples, momentum factors, and point-in-time filing conventions.
How should AMGN's current valuation multiple be interpreted? ↓
AMGN trades at a trailing P/E of 25.1x within the Health Care sector (moderate valuation corridor (15x - 30x p/e)). Valuation multiples are computed using trailing-twelve-month GAAP earnings against the latest close price.
What are AMGN's key momentum and technical factor indicators? ↓
As of the latest close, AMGN shows a 1-month return of +8.18%, 3-month return of +16.74%, and 12-month return of +48.41%, with a 14-day RSI of 69.5. Momentum factors reflect short- and intermediate-term price velocity across the equity cross-section.
What is Point-in-Time (PIT) financial data and why does it matter for AMGN? ↓
Point-in-Time indexing aligns corporate fundamentals with their official public filing timestamps (Form 10-Q/10-K) rather than accounting period-end dates. This methodology eliminates lookahead bias in historical equity backtests.
How can AMGN be incorporated into systematic factor models? ↓
AMGN can be evaluated within customized multi-factor models or screened against cross-sectional filters (such as momentum quintiles and return on equity) to analyze historical turnover and risk-adjusted return.